Kamada Ltd. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 12, 2026 at 8:20 PM GMT+3 3 min read

Kamada Ltd. Q2 2026 Earnings Call Summary - Moby

Strategic Growth Pillars and Operational Execution

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance was driven by strong double-digit growth across the existing commercial product portfolio, particularly KEDRAB in the U.S. and international markets.
Management attributes record financial results to a four-pillar strategy focusing on commercial sales, distribution expansion, plasma collection, and M&A.
Operational synergies and disciplined expense management allowed the company to maintain a 26% adjusted EBITDA margin despite shifting product mixes.
The company is successfully transitioning to a vertically integrated model, utilizing its own Texas-based plasma collection centers to support both external supply agreements and internal production.
The Distribution segment is expanding through the launch of biosimilars in Israel and new agreements in the MENA region to diversify revenue streams.
Strategic investments in post-marketing research for CYTOGAM are intended to demonstrate clinical advantages in transplant recipients and drive increased utilization.

Guidance Reiteration and Future Growth Drivers

Management reiterated 2026 annual guidance of $200 million to $205 million in revenue, assuming the commencement of plasma sales in the fourth quarter.
The new 3-year, $50 million plasma supply agreement is expected to contribute approximately $17 million annually, effectively utilizing the capacity of two collection centers.
Biosimilar annual sales are projected to reach between $15 million to $20 million within the next few years as more products from the pipeline are launched.
Future growth acceleration is contingent on the execution of M&A transactions, which remain a core focus to complement current organic double-digit growth.
The company expects to maintain its track record of converting operating profits into cash flow to support ongoing investments and shareholder returns.

Structural Changes and Operational Milestones

CFO Chaime Orlev will depart at the end of 2026 after nine years; a search for a successor has been initiated with a transition plan in place.
The company implemented a $14.4 million dividend payment during the second quarter, highlighting its strong cash position and operational health.
Approval of an in-house rabies antibody neutralizing test lab was secured to accelerate product release cycles and further vertical integration.
The first-of-its-kind $50 million normal source plasma agreement validates the company's investment in U.S.-based collection infrastructure.

Q&A Session Insights

Rationale for maintaining 2026 guidance despite record H1 performance

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management noted that H1 results represent approximately 50% of the annual midpoint, and they remain comfortable with the existing high-growth targets.
The company emphasized that the current guidance already reflects significant year-over-year growth of 12% in revenue and 23% in EBITDA.

Gross margin fluctuations and EBITDA sustainability

Management explained that gross margin varies quarter-to-quarter based on specific product and market mixes.
They emphasized the achievement of maintaining a consistent 26% EBITDA margin through operational synergies and scale.

Capacity and utilization of U.S. plasma collection centers

The $50 million contract fully commits the $16 million to $20 million annual capacity of the Houston and San Antonio centers.
A third center in Beaumont remains dedicated to specialty plasma for Kamada's internal product manufacturing.

Efficiency of selling and marketing expenses

Management attributed lower-than-expected marketing spend to effective resource utilization and the realization of economies of scale.
The focus remains on growing the bottom line in tandem with the top line through responsible resource management.